A novel EPAC1 inhibitor as anticancer drug


Chronic activation of cAMP/EPAC signaling leads to cardiac dysfunction inducing pathologic cardiac remodeling, and promoting cardiac arrhythmia and heart failure development.[marge] A new family of EPAC-1 inhibitors with cardioprotective effects has shown that the blockade of EPAC1 may provide a dual therapeutic advantage in cancer therapy by simultaneously preventing anthracyclines cardiotoxicity and reducing tumor growth.